Berlin: Bionth Biontech and As Pharma Pfizer, who jointly developed the Covid-19 vaccine in a short time, said Wednesday, they were working on shingling shots using the same MRNA technology.
Meanwhile, Modernum has announced that he has responded to his first volunteer for a vaccine against the Epstein-Barr (EBV) virus, the cause of mononucleosis.
Three companies utilize the same MRNA technology they use to develop a very successful Covid-19 vaccine on other diseases, in potential breakthrough moments for modern medicine.
Pfizer and Bionech signed a partnership agreement and aimed at clinical trials to start in the second half of 2022, they said in a shared statement.
“This collaboration aims to develop a new MRNA-based vaccine against Herpes Zoster, utilizing the expertise and resources of the two companies,” said Ogur Sahin, CEO and Co-Founder Bionech.
The RNA Messenger method made its debut with the Pfizer-Bionontech Coronavirus vaccine, which was the first JAD against Covid to be approved in the West at the end of 2020.
Herpes Zoster was a common disease throughout the world caused by the achievement of chickenpox which caused chicken pox.
This can cause very painful, tarnished skin patches, and in rare cases until facial paralysis, deafness and blindness.
Even though there are currently vaccines that are approved for Herpes Zoster, Pfizer and Bionech say they want to develop a better vaccine that has the potential to show high efficacy and a better tolerability.
The Coronavirus Jab developed by US Biotech Modera along with the US Government Agency of the National Institutes of Health (NIH) also uses MRNA technology.
Moderna said on Wednesday it was responded to 270 first participants aged 18-30 in clinical trials for vaccines against EBV – viruses that are currently not approved by vaccines.
EBV is very common, thinking of infecting more than 80 percent of Americans at the age of 19 years.
It spreads through body fluids, such as saliva, and is usually contracted in early childhood or teenagers.
Infection during adolescence is more symptoms, and can cause infectious mononucleosis (IM), sometimes called “kiss disease,” a condition that can cause fever, fatigue, sore throat and swelling lymph nodes.
Patients in some cases can be affected for weeks or months, sometimes needing hospitalization.
EBV is also a “latent virus” which can be reactivated in rare cases.
Scientists believe the MRNA vaccine, which provokes the immune response by providing genetic molecules that contain codes for important parts of pathogens into human cells, can be a game-changer against many diseases.
They also take less time to develop than traditional vaccines, which are generally based on inactive pathogens, or living but weak microbial forms.
Bionech is also working on MRNA-based malaria vaccines supported by the World Health Organization, African centers for controlling and prevention of disease and the European Union, with trials will begin at the end of 2022.
Pfizer develops the MRNA flu jab, such as modernna.
Moderna also develops vaccines against HIV and flu, among others.
Pfizer / bionech to develop mrna-based shingles
